Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Ukraine accuses Russia of invasion after aid convoy crosses border |
- British Muslims blame jihadi subculture after beheading video
- Exclusive: Apple iPhone 6 screen snag leaves supply chain scrambling
- Gunmen execute 18 alleged collaborators in Gaza
- For embattled Ukraine rebels, no time to honour the dead